Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.89 -4.5%	$2.12	$1.68 ▼ $6.63	$502.92M	2.07	1.38 million shs	964,031 shs
CGEM Cullinan Therapeutics	$8.92 -1.8%	$9.93	$7.90 ▼ $30.19	$521.94M	-0.12	466,786 shs	392,534 shs
DNTH Dianthus Therapeutics	$21.28 -2.8%	$22.65	$18.13 ▼ $33.77	$629.82M	1.82	226,836 shs	259,714 shs
FTLF FitLife Brands	$13.84 -0.4%	$15.26	$10.60 ▼ $17.75	$127.47M	0.95	16,989 shs	21,590 shs

7 Top Nuclear Stocks To Buy Now

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-4.55%	-8.70%	-1.05%	-24.10%	-65.51%
CGEM Cullinan Therapeutics	-1.76%	+4.82%	-9.07%	-24.09%	-47.47%
DNTH Dianthus Therapeutics	-2.83%	-9.52%	-8.90%	-10.63%	-27.37%
FTLF FitLife Brands	-0.43%	-5.72%	-9.31%	-18.59%	+27.56%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.1548 of 5 stars	3.5	3.0	2.8	3.3	0.6
CGEM Cullinan Therapeutics	2.2528 of 5 stars	3.5	1.0	2.4	2.5	0.6
DNTH Dianthus Therapeutics	1.3877 of 5 stars	3.6	0.0	1.9	1.7	0.0
FTLF FitLife Brands	4.6052 of 5 stars	3.8	5.0	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$10.40	450.26% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$32.86	268.35% Upside
DNTH Dianthus Therapeutics	3.20	Buy	$52.14	145.03% Upside
FTLF FitLife Brands	3.50	Strong Buy	$20.00	44.51% Upside

Current Analyst Ratings Breakdown

Latest FTLF, CGEM, DNTH, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00 ➝ $36.00
3/12/2025	DNTH Dianthus Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $84.00
3/12/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/7/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$38.00 ➝ $35.00
2/28/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
1/29/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
1/13/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
12/20/2024	DNTH Dianthus Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.09M	49.84	N/A	N/A	$0.64 per share	2.95
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
DNTH Dianthus Therapeutics	$5.37M	117.37	N/A	N/A	$11.40 per share	1.87
FTLF FitLife Brands	$62.76M	2.03	$0.73 per share	19.05	$3.04 per share	4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$1.21	N/A	N/A	N/A	N/A	-63.65%	-36.54%	3/20/2025 (Estimated)
CGEM Cullinan Therapeutics	-$153.16M	-$3.03	N/A	N/A	N/A	N/A	-26.54%	-25.32%	5/21/2025 (Estimated)
DNTH Dianthus Therapeutics	-$43.56M	-$2.50	N/A	N/A	N/A	-1,250.32%	-21.68%	-20.88%	3/20/2025 (Estimated)
FTLF FitLife Brands	$5.30M	$0.84	16.38	12.58	N/A	13.38%	28.03%	15.13%	N/A

Latest FTLF, CGEM, DNTH, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2025	N/A	AUTL Autolus Therapeutics	-$0.21	N/A	N/A	N/A	$2.98 million	N/A
3/20/2025	N/A	DNTH Dianthus Therapeutics	-$0.69	N/A	N/A	N/A	$0.86 million	N/A
3/11/2025	Q4 2024	DNTH Dianthus Therapeutics	-$0.85	-$0.81	+$0.04	-$0.81	$1.40 million	$1.33 million
2/27/2025	Q4 2024	CGEM Cullinan Therapeutics	-$0.75	-$0.73	+$0.02	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
CGEM Cullinan Therapeutics	N/A	24.46	24.46
DNTH Dianthus Therapeutics	N/A	18.30	18.30
FTLF FitLife Brands	0.28	1.50	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CGEM Cullinan Therapeutics	86.31%
DNTH Dianthus Therapeutics	47.53%
FTLF FitLife Brands	2.32%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CGEM Cullinan Therapeutics	6.07%
DNTH Dianthus Therapeutics	16.56%
FTLF FitLife Brands	61.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.09 million	197.71 million	Optionable
CGEM Cullinan Therapeutics	30	58.51 million	54.69 million	Optionable
DNTH Dianthus Therapeutics	80	29.60 million	24.70 million	Optionable
FTLF FitLife Brands	20	9.21 million	3.56 million	Not Optionable

FTLF, CGEM, DNTH, and AUTL Headlines

Recent News About These Companies

FitLife Brands, Inc. to Present at 37th Annual Roth Conference and Provides Financial Update for 2024 Performance

March 13 at 9:15 AM | quiverquant.com

FitLife Brands Announces its Participation at the 37th Annual Roth Conference and Provides Financial and Operational Update

March 13 at 8:30 AM | globenewswire.com

FitLife Brands (NASDAQ:FTLF) Shares Down 2.6% - What's Next?

March 8, 2025 | marketbeat.com

Short Interest in FitLife Brands, Inc. (NASDAQ:FTLF) Expands By 20.0%

March 7, 2025 | marketbeat.com

FitLife Brands, Inc. Schedules Release of Fourth Quarter and Full Year Fiscal 2024 Financial Results

March 7, 2025 | quiverquant.com

FitLife Brands Announces Fourth Quarter Earnings Call

March 7, 2025 | globenewswire.com

Do You Believe in the Growth Potential of FitLife Brands (FTLF)?

February 21, 2025 | msn.com

FitLife: A 'Roll-Up' Growth Story With A Lot Of Upside

February 20, 2025 | seekingalpha.com

FitLife Brands, Inc. (NASDAQ:FTLF) Short Interest Update

February 14, 2025 | marketbeat.com

Here’s Why Smoak Capital Sold Most of its Fitlife Brands (FTLF) Investment

February 14, 2025 | msn.com

Why FitLife Brands, Inc.’s (FTLF) Stock Is Down 48.67%

February 8, 2025 | aaii.com

FitLife Brands, Inc.: FitLife Brands Announces 2-for-1 Forward Stock Split

February 7, 2025 | finanznachrichten.de

FitLife Brands announces 2-for-1 stock split

February 6, 2025 | msn.com

FitLife Brands, Inc. Announces 2-for-1 Forward Stock Split Effective February 7, 2025

February 5, 2025 | quiverquant.com

FitLife Brands Announces 2-for-1 Forward Stock Split

February 5, 2025 | globenewswire.com

FitLife Brands, Inc. (FTLF): A Bull Case Theory

January 31, 2025 | msn.com

When the Price of (FTLF) Talks, People Listen

January 30, 2025 | news.stocktradersdaily.com

(FTLF) Technical Pivots with Risk Controls

January 19, 2025 | news.stocktradersdaily.com

Fitlife Brands director Todd Ordal acquires $4,555 in stock

January 16, 2025 | msn.com

Learn to Evaluate (FTLF) using the Charts

December 8, 2024 | news.stocktradersdaily.com

Investors in FitLife Brands (NASDAQ:FTLF) have seen incredible returns of 864% over the past five years

December 8, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF, CGEM, DNTH, and AUTL Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.89 -0.09 (-4.55%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$1.89 0.00 (0.00%)

As of 03/13/2025 06:33 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cullinan Therapeutics NASDAQ:CGEM

$8.92 -0.16 (-1.76%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$8.92 0.00 (0.00%)

As of 03/13/2025 04:02 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$21.28 -0.62 (-2.83%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$21.30 +0.02 (+0.07%)

As of 03/13/2025 04:01 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

FitLife Brands NASDAQ:FTLF

$13.84 -0.06 (-0.43%)

Closing price 03/13/2025 04:00 PM Eastern

Extended Trading

$13.84 +0.01 (+0.04%)

As of 03/13/2025 05:00 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time